Eli Lilly and Company (NYSE:LLY) is expected to report revenue of $5.2 Billion for the current quarter, according to consensus estimate of 11 analysts. The Company now has Insider ownership of 11.6 Percent and Institutional Ownership of 77.2 Percent.
Eli Lilly and Company is now showing 16.5% EPS growth this year.
01/15/2016 - Eli Lilly and Company had its "buy" rating reiterated by analysts at Argus.
LLY has been the topic of a number of other research reports. The company's shares were closed at $80.25. 4272836 shares were traded on Eli Lilly and Company's last session. The Market Cap of the company stands at 24.9 Billion. ETRADE Capital Management LLC now owns 12,904 shares of the company's stock worth $1,036,000 after buying an additional 3,531 shares during the last quarter. Finally, Covington Investment Advisors Inc. raised its stake in Eli Lilly and Company by 130.1% in the third quarter. 3 analysts are of a belief the stock is a "Hold".
Analysts' mean recommendation for Eli Lilly and Company's (LLY) stands at 2.00. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $83.79.
In recent trade, the price was 26.21% up its 200 day moving average and was brought 2.53% up versus its 50-day simple moving average. During the same quarter in the previous year, the business earned $0.89 EPS.
Eli Lilly and Company's (LLY) is a part of Healthcare sector and belongs to Drug Manufacturers - Major industry. The reported earnings per share topped the analyst's consensus by $0.01 with the percentage difference between estimated and actual earnings arriving at 0.90%.
02/10/2016 - Eli Lilly and Company had its "buy" rating reiterated by analysts at Deutsche Bank. The company had revenue of $5.76 billion for the quarter, compared to the consensus estimate of $5.54 billion. The stock has earnings growth of 61.60% yoy and showed a low EPS growth of -8.00% over the past five years. Eli Lilly and Company's revenue was up 7.2% compared to the same quarter previous year. Looking at the stock's movement on the chart, Eli Lilly and Company recorded a 52-week high of $82.16.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 10th.
The Average Volume of the company is 2.73 Million, while the Relative Volume of the company is 1.06. This represents a $2.08 annualized dividend and a yield of 2.84%. LLY has P/E (Price to Earnings ttm) value of 30.55, Forward P/E of 17.96, P/C (Price to cash per share) of 0 and Price to Free Cash Flow (P/FCF) value of 0. The correct version of this report can be read at [[permalink]]. The mean PT is calculated considering the consensus of 20 analysts. Goldman Sachs Group, Inc. Barclays PLC raised their price target on Eli Lilly and Company from $80.00 to $85.00 and gave the company a "buy" rating in a report on Wednesday, February 1st.
Eli Lilly and Company (NYSE:LLY) has received a short term rating of buy from experts at Zacks with a rank of 2. Credit Suisse Group restated a "focus list" rating and issued a $87.00 price objective on shares of Eli Lilly and Company in a research report on Monday, December 19th. Over the same time span, the stock marked US$23.58 as its best level and the lowest price reached was US$14.84. At present, 0 analysts call it Sell, while 5 think it is Hold. The company presently has a consensus rating of "Buy" and an average price target of $86.41. The shares were purchased at an average cost of $71.85 per share, for a total transaction of $35,925.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of 3.35%. Following the transaction, the senior vice president now directly owns 67,802 shares in the company, valued at approximately $4,925,815.30.